Onxeo Receives Notice of Allowance for a New Patent Broadening the Protection of AsiDNA™ in combination with a PARP Inhibitor in the United States
June 09, 2021 12:38 ET
|
Onxeo SA
PARIS, June 09, 2021 (GLOBE NEWSWIRE) -- Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO) (hereafter “Onxeo” or “the Company”), a clinical-stage biotechnology company specializing in the...
Onxeo Announces Formation of Scientific Advisory Committee of Leading Independent Experts
May 31, 2021 01:00 ET
|
Onxeo SA
PARIS, May 31, 2021 (GLOBE NEWSWIRE) -- Onxeo S.A. (Euronext Growth Paris: ALONX, Nasdaq First North: ONXEO), « Onxeo », a clinical-stage biotechnology company specializing in the development of...
Onxeo Reports Full-Year 2020 Financial Results and Provides Business Update
April 21, 2021 13:12 ET
|
Onxeo SA
Several major clinical milestones achieved in 2020 by AsiDNA™, including promising initial results in combination with chemotherapy and the launch of a new study to evaluate the abrogation of...
Onxeo to Present New Preclinical Data at AACR 2021
April 08, 2021 12:41 ET
|
Onxeo SA
Confirming the effect of AsiDNA™ on resistance to KRAS inhibitorsIntroducing OX400, a new generation of PARP interfering cancer drug candidates PARIS, April 08, 2021 (GLOBE NEWSWIRE) -- Onxeo...
Onxeo Announces Completion of Patient Enrollment in DRIIV-1b Study and Positive Interim Results
November 09, 2020 12:00 ET
|
Onxeo SA
The last patient was treated with AsiDNA™ in combination with carboplatin and paclitaxel in this Phase 1b study in patients with advanced solid tumors.The good safety profile of AsiDNA™ is confirmed...
Onxeo Receives Notice of Intent to Grant a New Patent Enhancing the Protection in Europe of AsiDNA™ Combined with PARP Inhibitors
October 22, 2020 12:00 ET
|
Onxeo SA
PARIS, France, Oct. 22, 2020 (GLOBE NEWSWIRE) -- Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), hereafter “Onxeo” or “the Company”, a clinical-stage biotechnology company specializing in the...
Onxeo Announces Enrollment of First Patient in Phase Ib/II Study Revocan
October 21, 2020 13:30 ET
|
Onxeo SA
Revocan is designed to evaluate the abrogation by AsiDNA™ of tumor resistance to a PARP inhibitor in relapsed ovarian cancerFirst results from Revocan are expected early 2021 PARIS, Oct. 21, 2020 ...
Onxeo Reports its Financial Results for the First Half of 2020 and Provides an Update on its Activities
September 17, 2020 12:29 ET
|
Onxeo SA
The cash position of €19.6 million, which was strengthened in the first half of the year by two strategic transactions, provides financial visibility into Q1 2022Patient inclusion process has started...
Onxeo to Attend Key Investor Conferences and Events in the Second Half of 2020
September 08, 2020 08:00 ET
|
Onxeo SA
PARIS, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the Company”), a clinical-stage biotechnology company specializing in the development of...
Onxeo Receives Notice of Allowance from USPTO for New Patent Strengthening Protection of AsiDNA™ via Systemic Administration in the United States
September 03, 2020 12:00 ET
|
Onxeo SA
This new patent will add to the protection of AsiDNA™ and its related compounds for their use via systemic administration in the treatment of TNBC and chemo-resistant lung cancer, alone or in...